Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Japan’s Asahi Kasei in $1.1 Billion Deal to Acquire Calliditas

publication date: May 29, 2024

Asahi Kasei, a Japanese conglomerate known mainly for its chemicals and building materials, made a $1.1 billion offer to buy Calliditas Therapeutics of Sweden. Calliditas is a company focused on rare diseases with one FDA approved drug, Tarpeyo (a delayed-release formulation of the steroid budesonide budesonide) for primary immunoglobulin A nephropathy (IgAN). IgAN is a chronic kidney disease caused by the buildup of antibodies. Asahi Kasei has a medical subsidiary that provides filters for dialysis machines and other conditions. The company wants to have a larger presence in healthcare and plans to expand into the areas of immunology and transplantation. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here